中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2013年
10期
1641-1642
,共2页
星形胶质细胞瘤%MRI%临床研究
星形膠質細胞瘤%MRI%臨床研究
성형효질세포류%MRI%림상연구
AG%MRI%Protective effect%Clinical Research
目的::探讨星形胶质细胞瘤(AG)瘤-脑界面、瘤周水肿MRI像与临床病理之间的关系。方法:对78例AG患者MRI中瘤-脑界面、瘤周水肿的特征进行分析,判断星形胶质细胞瘤的类型和病理分级。结果:78例AG患者中,在加权像上,有11例未发现水肿,瘤周水肿发病率为85.9%;通过瘤周浸润增强分析,发现Ⅰ级与Ⅱ级和Ⅲ~Ⅳ级相比,强化程度和浸润程度有显著性差异(P<0.01);在增强程度的差异也有统计学意义(P<0.05);Ⅰ级AG与Ⅱ级和Ⅲ~Ⅳ级相比,有显著性差异(P<0.01),而Ⅱ级与Ⅲ~Ⅳ级相比,无明显差异(P>0.05)。结论:瘤-脑界面MRI强化的形态和程度以及瘤周水肿均与AG细胞瘤的恶性程度有关。
目的::探討星形膠質細胞瘤(AG)瘤-腦界麵、瘤週水腫MRI像與臨床病理之間的關繫。方法:對78例AG患者MRI中瘤-腦界麵、瘤週水腫的特徵進行分析,判斷星形膠質細胞瘤的類型和病理分級。結果:78例AG患者中,在加權像上,有11例未髮現水腫,瘤週水腫髮病率為85.9%;通過瘤週浸潤增彊分析,髮現Ⅰ級與Ⅱ級和Ⅲ~Ⅳ級相比,彊化程度和浸潤程度有顯著性差異(P<0.01);在增彊程度的差異也有統計學意義(P<0.05);Ⅰ級AG與Ⅱ級和Ⅲ~Ⅳ級相比,有顯著性差異(P<0.01),而Ⅱ級與Ⅲ~Ⅳ級相比,無明顯差異(P>0.05)。結論:瘤-腦界麵MRI彊化的形態和程度以及瘤週水腫均與AG細胞瘤的噁性程度有關。
목적::탐토성형효질세포류(AG)류-뇌계면、류주수종MRI상여림상병리지간적관계。방법:대78례AG환자MRI중류-뇌계면、류주수종적특정진행분석,판단성형효질세포류적류형화병리분급。결과:78례AG환자중,재가권상상,유11례미발현수종,류주수종발병솔위85.9%;통과류주침윤증강분석,발현Ⅰ급여Ⅱ급화Ⅲ~Ⅳ급상비,강화정도화침윤정도유현저성차이(P<0.01);재증강정도적차이야유통계학의의(P<0.05);Ⅰ급AG여Ⅱ급화Ⅲ~Ⅳ급상비,유현저성차이(P<0.01),이Ⅱ급여Ⅲ~Ⅳ급상비,무명현차이(P>0.05)。결론:류-뇌계면MRI강화적형태화정도이급류주수종균여AG세포류적악성정도유관。
Objective:Explore the the astrocytoma (AG) tumors-brain interface, and the relationship between peritumoral edema in MRI image and clinical pathology.Methods:Analysis of 78 cases AG patients MRI tumor-brain interface characteristics of peritumoral edema,determine the type and pathological grade of glioblastoma.Results:78 cases of AG patients,with weighted images,11 cases found no edema, peritumoral edema incidence rate of 85.9%;peritumoral infiltration enhanced analysis,we can find thatⅠand gradeⅡand gradeⅢ~Ⅳcompared to strengthen the extent and degree of infiltration significant difference (P<0.01);differences in the degree of enhancement is also statistically significant (P<0.05);Compared of gradeⅠAG gradeⅡand gradeⅢ~Ⅳ, a significant difference (P<0.01), gradeⅡand gradeⅢ~Ⅳwas no significant difference (P>0.05).Conclusion:The shape and extent of the tumor-brain interface MRI strengthen and peritumoral edema are related to the degree of malignancy of the AG cell tumor.